Fundraising Fox

Immutrin

5 known investors

Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis. Its lead program targets ATTR cardiomyopathy, a progressive form of amyloidosis.

BiotechMedical Devices

Founders & leadership

MPMark Pepys
Mark PepysCo-founder; Emeritus Professor of Medicine at UCL
GWGregory Winter
Gregory WinterCo-founder; Nobel Laureate
DCDaniel Christ
Daniel ChristCo-founder; Professor, Faculty of Medicine, UNSW

Investors · 5

Cambridge Innovation Capital✓ verifiedCambridge · $127K – $12.7M
Frazier Life Sciences✓ verifiedPalo Alto
Qiming Venture Partners✓ verifiedBeijing · $5M – $134M
F-Prime CapitalCambridge · $3M – $10M
SR One Capital ManagementRedwood City

Funding

SEC filings, press & company announcements

$173.4M disclosed across 2 rounds · 2026

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Immutrin raises £65m to advance antibody therapy - Drug Discovery World (DDW)ddw-online.com · Apr 2026Immutrin raises £65 million in Series A funding to advance amyloidosis therapy - The Milner Therapeutics Institutemilner.cam.ac.uk · Mar 2026Immutrin raises £65 million Series A to develop next generation antibody therapy for ATTR amyloidosisenterprise.cam.ac.uk · Mar 2026Immutrin Raises $87 Million to Advance ATTR-CM Therapy - Global Genesglobalgenes.org · Mar 2026Immutrin secures $86M for antibody programendpoints.news · Mar 2026Immutrin raises $87M to advance drug for progressive heart disease | BioPharma Divebiopharmadive.com · Mar 2026

Frequently asked questions

What does Immutrin do?
Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis. Its lead program targets ATTR cardiomyopathy, a progressive form of amyloidosis.
Who founded Immutrin?
Immutrin was founded by Mark Pepys, Gregory Winter, Daniel Christ.
Who are Immutrin's investors?
Immutrin's investors include Cambridge Innovation Capital, Frazier Life Sciences, Qiming Venture Partners, F-Prime Capital, SR One Capital Management.
How much funding has Immutrin raised?
Immutrin has disclosed $173.4M raised across 2 rounds.